Conclusions
HDM-SLIT-tablet is a safe and well-tolerated AR treatment. AEs occur
often but are mostly mild and decreasing during the first year. CARAT
scores improved and symptomatic medication use decreased suggesting
better control of AR with HDMSLIT-tablet treatment. Compliance,
tolerability, and treatment satisfaction are good. However, patient
follow-up and compliance remain important points of attention when
starting HDM SLIT-tablet.
Keywords: Allergic Rhinitis, Control of Allergic Rhinitis and
Asthma Test (CARAT), House dust mite (HDM), Safety, Sublingual
immunotherapy tablet